Company / R&D Expense
OMEROS CORP R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$119.5M
FY2024
5-year range
$107.6M / $119.5M
FY2020-FY2024
Trend
+4.1%
vs FY2023
Sector context
#122 of 210
Health Care
What the data says
At $120M, OMEROS CORP's r&d expense ranks #122 of 210 in the Health Care sector. Improved from $113M to $120M over the past 2 years.
Based on SEC 10-K filings.
$120M in FY2024 with a 5-year CAGR of +2.4%.
Improved from $113M to $120M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +0.2%
- 5-Year CAGR
- +2.4%
- 10-Year CAGR
- -
Sector benchmark
#122 of 210 in Health CareTop 58% of 210This company $119.5M Sector average $644.0M
▼
-81.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.4%, indicating consistent growth.
- In FY2024, r&d expense increased 4.1% year-over-year.
- Ranks #122 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.92 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $119.5M | +4.1% |
| FY2023 | $114.9M | +1.9% |
| FY2022 | $112.7M | -5.1% |
| FY2021 | $118.8M | +10.4% |
| FY2020 | $107.6M | +1.2% |
| FY2019 | $106.3M | +18.3% |
| FY2018 | $89.9M | +61.6% |
| FY2017 | $55.6M | +9.7% |
| FY2016 | $50.7M | +39.7% |
| FY2015 | $36.3M | -24.3% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026